Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies

Background: In 2014, six of the top ten blockbuster medicines were monoclonal antibodies. This multibillion-dollar market with expiring patents is the main driver for the development of biosimilar mAbs. With the ever-increasing cost of healthcare and the economic pressure to reduce or sustain health...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Front Pharmacol
Hoofdauteurs: Moorkens, Evelien, Jonker-Exler, Clara, Huys, Isabelle, Declerck, Paul, Simoens, Steven, Vulto, Arnold G.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Frontiers Media S.A. 2016
Onderwerpen:
Pharmacology
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4925708/
https://ncbi.nlm.nih.gov/pubmed/27445826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00193
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items